相关临床试验
85
45 进行中
药物批准
13
批准总数
监管机构
4
监管机构数
成立时间
N/A
进行中（未招募）
43
50.6%
已完成
28
32.9%
尚未招募
2
2.4%
招募中
9
10.6%
暂停
1
1.2%
撤回
2
2.4%
- The EMA's CHMP recommended 12 new medicines for approval at its September 14-17, 2026 meeting, alongside 11 therapeutic indication extensions and two biosimilars. - Povofortay (povorcitinib) became the first oral daily treatment recommended for adults with moderate to severe hidradenitis suppurativa refractory or intolerant to anti-TNF therapy. - Johnson & Johnson's Tecvayli (teclistamab) won support for earlier-line multiple myeloma use, with MajesTEC-3 data showing a 71% reduction in progression risk versus standard of care. - Two initial marketing applications were withdrawn, for apitegromab in 5q spinal muscular atrophy and trilaciclib in extensive-stage small-cell lung cancer, while three negative opinions entered re-examination.
- China Medical System Holdings Limited has entered into an exclusive 15-year commercialization agreement with Pharmacosmos A/S for two intravenous iron products, Monofer® and Cosmofer®, in mainland China. - Monofer® represents the first third-generation intravenous iron therapy approved in China, featuring innovative nanostructure technology that enables single-dose full iron replenishment of 1,000 mg or more. - The partnership addresses significant unmet medical needs in China, where iron deficiency anemia affects 20.1% of residents but remains underdiagnosed and undertreated. - Both products are included in China's National Reimbursement Drug List, with Cosmofer® holding Category A status and inclusion in the National Essential Medicines List.
